This is a free sample of content from Addiction.
Click here for more information or to buy the book.

# Index

A
Acamprosate
  historical perspective, 3
  mechanism of action, 3
Acetylcholine (ACh). *See also* Choline acetyltransferase; Nicotinic acetylcholine receptor
  pools, 271
  therapeutic targeting in nicotine addiction
    acetylcholinesterase inhibitors, 273
    dietary supplements, 272–273
*N*-Acetylcysteine (NAC), cocaine addiction management, 6
ACh. *See* Acetylcholine
Adolescence. *See* Nicotine
2-AG. *See* 2-Arachidonylglycerol
Alcohol dependence
  central amygdala studies
    disinhibition model of output, 302–303
    γ-aminobutyric acid
      acute alcohol effects, 297–298
      chronic alcohol effects, 298–299
      GABAergic system overview, 297
    glutamatergic transmission
      acute alcohol effects, 299
      chronic alcohol effects, 300
      overview, 299
    neuropeptides
      corticotrophin-releasing factor, 300–301
      neuropeptide Y, 302
      nociceptin, 301–302
      overview, 300
    prospects for study, 303
  escalation of use in animals, 11
  *N*-methyl-D-aspartate receptor, ethanol effects
    acute effects
      GluN1, 282
      GluN2, 282–283
      overview, 282
      posttranslational effectors, 283
    basolateral amygdala, 288
    bed nucleus of the stria terminalis receptors, 286–288
    central amygdala, 288
    chronic effects, 284
    plasticity effects, 284–285
    prospects for study, 288–289
  opioid receptor modulation
    μ-opioid receptor
      A118G polymorphism studies, 310–313
      overview, 309–310
    naltrexone studies, 310, 313–315
AMPA receptor
  nicotine studies
    dependence role, 252–253
    reinforcing effects, 253
    reward-enhancing effects, 258
  nucleus accumbens and cocaine effects
    chronic administration studies, 122–123
    overview, 121–122
    prospects for study, 129–130
    receptor trafficking and cocaine-induced plasticity, 123–124
    reinstatement of drug seeking
      GluA1 subunit-containing receptors, 124–127
      GluA2 subunit-containing receptors, 127–129
  opiate effects on AMPA/NMDA receptor ratio, 158
  opiate memory mechanisms
    ascending dopamine pathways, 176–177
    basolateral amygdala outputs, 175–176
    conditioned reinforcement, 171
    conditioned reward and aversion, 170–171
    extinction and reinstatement, 171, 173
    hippocampus, 176
    overview, 172
    prefrontal-accumbens pathways, 174–175
    prospects for study, 177
    systems perspective, 173–174
  psychostimulant-induced neuroadaptation, 82–84
  relapse neurobiology, 50–51
  ventral tegmental area, cocaine-evoked synaptic plasticity of excitatory transmission
    AMPA receptor/NMDA receptor ratio, 112–116
    excitatory postsynaptic potentials, 114–115
Amygdala. *See also* Basolateral amygdala; Central nucleus of the amygdala
  reward circuitry, 72–75
Anandamide
  dopamine signaling regulation during cue-motivated behavior, 327–328
  opioid withdrawal role, 207



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



Animal models, addiction. *See also specific drugs*
drug preference for nondrug rewards, 14–15
DSM-IV criteria appearance, 10
escalation of drug use, 10–11
extinction resistance, 12–13
historical perspective, 2
motivation for drug, 13–14
neurocognitive deficits, 11–12
prospects for study, 17
punishment resistance, 15–16
Anterior cingulate, mesocorticolimbic dopamine pathway, 45
Anxiety
bed nucleus of the stria terminalis mediation, 285–286
nicotine effects, 216
Appetite
nicotine effects, 217–218
nicotinic acetylcholine receptor modulation, 217–218
2-Arachidonylglycerol (2-AG)
dopamine signaling regulation during cue-motivated behavior, 327–328
opioid withdrawal role, 207
Aripirazole, indications, 6
Attention, nicotine effects, 215–217

B

Basolateral amygdala (BLA). *See also* Amygdala
drug-associated learning, 45
*N*-methyl-D-aspartate receptor response to alcohol, 288
opiate memory and glutamate receptors, 175–176
optogenetics, 64–65, 67
relapse neurobiology, 49–51
BDNF. *See* Brain-derived neurotrophic factor
Bed nucleus of the stria terminalis (BNST)
connectivity, 285
mesocorticolimbic dopamine pathway, 45
*N*-methyl-D-aspartate receptor response to alcohol, 286–288
relapse neurobiology, 52
stress and anxiety mediation, 285–286
BLA. *See* Basolateral amygdala
BNST. *See* Bed nucleus of the stria terminalis
Brain-derived neurotrophic factor (BDNF)
cocaine addiction
epigenetic regulation, 144–146
role, 143–144
CREB regulation, 105
opiate effects in ventral tegmental area, 158–159, 191–192
Buprenorphine
naloxone combination. *See* Suboxone
opioid choice effects, 203–204
Buproprion, nicotine addiction management, 5, 275

C

Calcium/calmodulin protein kinase II (CaMKII), AMPA receptor modulation in nucleus accumbens, 126–127
CaMKII. *See* Calcium/calmodulin protein kinase II
Cannabinoids
cannabinoid receptors in central nervous system, 334–335
$\Delta^9$-tetrahydrocannabinol
hippocampus synaptic transmission, acute effects
excitatory synaptic transmission, 335–336
inhibitory synaptic transmission, 336
lasting synaptic effects after acute exposure, 338–339
non-cannabinoid receptor acute effects in brain, 337–338
overview of effects, 333–334
prospects for study, 343
synaptic effects after long-term exposure
cerebellum, 340
dorsal striatum, 341–342
hippocampus, 340–341
nucleus accumbens, 339
dopamine release
stimulation by cannabinoids
pharmacological mechanisms, 322–323
phasic events, 321–322
tonic levels, 321
tonic versus phasic, 320–321
withdrawal effects, 323–324
endocannnabinoid system
dopamine release effects, 324
overview, 324
signaling disruption effects
cue-evoked dopamine release, 326–327
drug-induced dopamine release, 324–326
Cdk5. *See* Cyclin-dependent kinase-5
CeA. *See* Central nucleus of the amygdala
Central nucleus of the amygdala (CeA). *See also* Amygdala
alcohol dependence studies
disinhibition model of output, 302–303
γ-aminobutyric acid
acute alcohol effects, 297–298
chronic alcohol effects, 298–299
GABAergic system overview, 297
glutamatergic transmission
acute alcohol effects, 299
chronic alcohol effects, 300
overview, 299



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



neuropeptides
corticotrophin-releasing factor, 300–301
neuropeptide Y, 302
nociceptin, 301–302
overview, 300
prospects for study, 303
*N*-methyl-D-aspartate receptor response to alcohol, 288
negative emotional circuitry, 296–297
relapse neurobiology, 52
Cerebellum, THC effects on synaptic transmission, 340
Channelrhodopsin-2. *See* Optogenetics
ChAT. *See* Choline acetyltransferase
Choline acetyltransferase (ChAT)
acetylcholine synthesis, 270
polymorphisms
rodents, 272
smokers, 272
Chromatin modification. *See* Epigenetics
Clonidine, opioid choice effects, 206–207
Cocaine addiction
animal studies
escalation of drug use, 11, 16
motivation for drug, 13–14
epigenetics. *See* Epigenetics
multi-symptomatic model, 25, 29
nucleus accumbens AMPA receptor transmission effects
chronic administration studies, 122–123
overview, 121–122
prospects for study, 129–130
receptor trafficking and cocaine-induced plasticity, 123–124
reinstatement of drug seeking
GluA1 subunit-containing receptors, 124–127
GluA2 subunit-containing receptors, 127–129
structural plasticity changes. *See* Structural plasticity
vaccine therapy, 6
ventral tegmental area, cocaine-evoked synaptic plasticity of excitatory transmission
AMPA receptor excitatory postsynaptic potentials, 114–115
AMPA receptor/NMDA receptor ratio, 112–116
induction mechanism and mesolimbic dopamine, 112–114
NMDA receptor excitatory postsynaptic potentials, 115–116
synaptic function consequences, 115–116
vulnerability
animal models
diagnosis, 29, 31–33
multi-symptomatic model of addiction, 29
novelty responses, 34–37
overview, 28–29
rat responders, 29
validation, 32, 34
contributing factors
complex interactions, 27–28
drug type, 26
overview, 25–26
personality traits, 26
prospects for study, 37
Cognition
adolescent nicotine exposure and performance impact in later life, 228–231
neurocognitive deficits in animal addiction, 11–12
Conditioned place preference (CPP)
alcoholism, 302
cocaine seeking, 127, 143
nicotine addiction, 258, 263
opioid addiction, 149, 170–173, 175, 177
vulnerability to addiction, 35
Corticotrophin-releasing factor (CRF)
alcohol effects in bed nucleus of the stria terminalis, 286
AMPA receptor/NMDA receptor ratio modulation, 113–114
central amygdala alcohol dependence studies, 300–301
opioid withdrawal role, 207
relapse neurobiology, 52
CPP. *See* Conditioned place preference
CREB. *See* Cyclic AMP response element-binding protein
CRF. *See* Corticotrophin-releasing factor
Cyclic AMP response element-binding protein (CREB)
activation
behavioral consequences, 101–103
cellular and molecular consequences, 99–101
epigenetic regulation, 138
nucleus accumbens drug reward circuitry, 103–104
opiate effects in locus coeruleus, 161,164
psychostimulant-induced structural plasticity, 85, 87
transcriptional activation mechanism
extracellular signals and stimuli, 99
intracellular signals, 98–99
overview, 96–97
treatment implications, 104–105
Cyclin-dependent kinase-5 (Cdk5), psychostimulant-induced structural plasticity, 87–88

## D

$\Delta^9$-Tetrahydrocannabinol. *See* Cannabinoids
Dendritic morphology. *See also* Structural plasticity
orbitofrontal cortex and psychostimulant effects, 49
psychostimulant-induced changes, 72
stress and environment effects, 81
techniques for study, 80
Depression, nicotine effects, 216



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



Disulfiram, alcohol addiction management, 4
DNA methylation. *See* Epigenetics
Dopamine
  cannabinoids and release
    stimulation by cannabinoids
      pharmacological mechanisms, 322–323
      phasic events, 321–322
      tonic levels, 321
    tonic versus phasic, 320–321
    withdrawal effects, 323–324
  endocannnabinoid system
    dopamine release effects, 324
    overview, 324
    signaling disruption effects
      cue-evoked dopamine release, 326–327
      drug-induced dopamine release, 324–326
  nicotine and signaling
    modulation by nicotine, 239–241
    withdrawal adaptations, 241–243
Dopamine receptor
  antagonist therapy overview, 5–6
  classification, 5
  relapse neurobiology, 50
Dorsal striatum, THC effects on synaptic transmission, 341–342
Drug classification, drugs of abuse, 45
Dynorphin
  behavioral consequences of induction, 102–103
  nucleus accumbens drug reward circuitry, 103–104
  opioid withdrawal role, 207

E

Ecstasy, structural plasticity effects, 81
Epigenetics
  chromatin structural changes and gene transcription, 136
  cocaine addiction
    brain-derived neurotrophic factor epigenetic regulation, 144–146
    genome-wide studies of chromatin regulation
      microRNAs, 141–143
      overview, 141
  DNA methylation, psychostimulant-induced changes
    behavioral responses, 140
    gene transcription, 140
  histone acetylation, psychostimulant-induced changes
    behavioral responses, 137–138
    gene transcription, 136–137
  histone methylation, psychostimulant-induced changes
    behavioral responses, 139–140
    gene transcription, 138–139
  prospects for addiction studies, 146
Ethanol. *See* Alcohol dependence
Extinction, resistance in animal addiction, 12–13

F

FAAH. *See* Fatty acid amide hydrolase
Fatty acid amide hydrolase (FAAH), inhibitor development, 207–208
Fos, psychostimulant-induced structural plasticity, 85

G

GABA. *See* γ-Aminobutyric acid
$GABA_A$ receptor
  cannabinoid modulation of dopamine release, 323
  ventral tegmental area receptors and opiate motivation
    brain-derived neurotrophic factor in switching, 191–192
    inhibitory and excitatory properties, 187–188
    integrated model of motivation, 192–193
    motivational switching mechanism, 190–191
    overview, 187
    signaling switch mechanisms, 188–189
$GABA_B$ receptor, nicotine dependence role, 261–264
γ-Aminobutyric acid (GABA)
  central amygdala alcohol dependence studies
    acute alcohol effects, 297–298
    chronic alcohol effects, 298–299
    GABAergic system overview, 297
  nicotine dependence studies
    conditioned behavioral responses, 262–264
    overview, 260–261
    prospects for study, 264
    reinforcing effects, 261–262
    reward-enhancing effects, 262
    seeking behavior, 264
    withdrawal, 264
  receptors. *See* $GABA_A$ receptor; $GABA_B$ receptor
Glutamate receptors. *See specific receptors*

H

Habenula
  anatomy, 213
  nicotine withdrawal role, 243–245
  nicotinic acetylcholine receptors in mesolimbic system and nicotine reinforcement, 213–215
Halorhodopsin. *See* Optogenetics
Hippocampus
  drug-associated learning, 45
  opiate memory and glutamate receptors, 176
  reward circuitry, 72–75
  THC effects on synaptic transmission
    acute effects
      excitatory synaptic transmission, 335–336



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



inhibitory synaptic transmission, 336
long-term exposure, 340–341
Histone modification. *See* Epigenetics

I

Incentive sensitization theory, addiction, 44
Interpenducular nucleus (IPN)
nicotine withdrawal role, 243–245
nicotinic acetylcholine receptors in mesolimbic system and nicotine reinforcement, 213–215
IPN. *See* Interpenducular nucleus

L

LC. *See* Locus coeruleus
Locus coeruleus (LC)
anatomy, 161
opiate effects
cellular plasticity changes, 161–163
structural plasticity changes, 163
Long-term depression (LTD)
nicotine effects in adolescents, 226
opiate effects, 156
psychostimulant-induced neuroadaptation, 82–84
THC effects, 338
Long-term potentiation (LTP)
opiate effects, 155–156
psychostimulant-induced neuroadaptation, 82–84
THC effects, 338
LTD. *See* Long-term depression
LTP. *See* Long-term potentiation

M

MAGL. *See* Monoacylglycerol lipase
Marijuana. *See* Cannabinoids
MDMA. *See* Ecstasy
MEF2. *See* Monocyte enhancing factor-2
Mesopontine rostromedial tegmental nucleus (rMTg)
dopamine system, 238–239
relapse neurobiology, 52
Metabotropic glutamate receptor (mGlu)
nicotine studies
dependence role, 252
mGluR2 and adolescent prefrontal cortex response to nicotine, 227
reinforcing studies, 254–255
reward-enhancing effects, 258
seeking behavior, 259
withdrawal, 259–260
opiate memory mechanisms and mGluR2/3
ascending dopamine pathways, 176–177
basolateral amygdala outputs, 175–176
conditioned reinforcement, 171
conditioned reward and aversion, 170–171
extinction and reinstatement, 171, 173
hippocampus, 176
overview, 172
prefrontal-accumbens pathways, 174–175
prospects for study, 177
systems perspective, 173–174
Methadone
compliance, 3
historical perspective, 2–3
*N*-Methyl-D-aspartate receptor (NMDAR)
alcohol effects in central amygdala, 299–300
CREB modulation, 100
ethanol effects
acute effects
GluN1, 282
GluN2, 282–283
overview, 282
posttranslational effectors, 283
basolateral amygdala, 288
bed nucleus of the stria terminalis receptors, 286–288
central amygdala, 288
chronic effects, 284
plasticity effects, 284–285
prospects for study, 288–289
nicotine studies
conditioned rewarding effects, 258–259
dependence role, 252–253
reinforcing effects, 253–254, 256
opiate studies
AMPA/NMDA receptor ratio, 158
opiate memory mechanisms
ascending dopamine pathways, 176–177
basolateral amygdala outputs, 175–176
conditioned reinforcement, 171
conditioned reward and aversion, 170–171
extinction and reinstatement, 171, 173
hippocampus, 176
overview, 172
prefrontal-nucleus accumbens pathways, 174–175
prospects for study, 177
systems perspective, 173–174
relapse neurobiology, 51
ventral tegmental area, cocaine-evoked synaptic plasticity of excitatory transmission
AMPA receptor/NMDA receptor ratio, 112–116
NMDA receptor excitatory postsynaptic potentials, 115–116
synaptic function consequences, 115–116
mGlu. *See* Metabotropic glutamate receptor
MicroRNA, cocaine addiction studies of epigenetic regulation, 141–143
Mitogen- and stress-activated protein kinase-1 (MSK1), epigenetic regulation, 139



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



Monoacylglycerol lipase (MAGL), inhibitor development, 207–208
Monocyte enhancing factor-2 (MEF2), psychostimulant-induced structural plasticity, 87–88
MSK1. *See* Mitogen- and stress-activated protein kinase-1
Multi-symptomatic model of addiction, 25, 29

N

NAC. *See N*-Acetylcysteine
NAcc. *See* Nucleus accumbens
nAChR. *See* Nicotinic acetylcholine receptor
Naloxone, buprenorphine combination. *See* Suboxone
Naltrexone
  alcohol addiction management, 3–4
  alcoholism studies, 310, 313–315
  formulations, 4
Neuropeptide Y (NPY), central amygdala alcohol dependence studies, 302
NF-κB. *See* Nuclear factor-κB
Nicotine
  γ-aminobutyric acid in dependence
    conditioned behavioral responses, 262–264
    overview, 260–261
    prospects for study, 264
    reinforcing effects, 261–262
    reward-enhancing effects, 262
    seeking behavior, 264
    withdrawal, 264
  choline acetyltransferase polymorphisms in smokers, 272
  dependence phases, 252
  dopamine signaling
    modulation by nicotine, 239–241
    withdrawal adaptations, 241–243
  glutamate receptors in dependence
    conditioned rewarding effects, 258–259
    overview, 252–253
    reinforcing effects, 253–256
    reward-enhancing effects, 256–257
    seeking behavior, 259
    withdrawal, 259–260
  neurochemistry, 270
  pharmacogenetic cessation treatment of smoking, 274–275
  pharmacotherapy of addiction. *See specific drugs*
  prefrontal cortex function effects in adolescents
    cognitive performance impact in later life, 228–231
    immediate effects, 225–226
    long-term consequences, 228–229
    mGluR2 expression, 227
    nicotinic acetylcholine receptor expression, 225–228
    prospects for study, 231
    vulnerability versus adult brain, 224–225
  smoking effects on depression, appetite, and attention, 215–218
  smoking mortality, 269
  structural plasticity effects, 81
  withdrawal and habenula-interpeduncular pathway, 213–215, 243–245
Nicotine replacement therapy, historical perspective, 4–5
Nicotinic acetylcholine receptor (nAChR)
  adolescent prefrontal cortex response to nicotine, 225–228
  aversion and nicotine withdrawal role in habenula-interpeduncular pathway, 213–215, 243–245
  food intake regulation, 217–218
  polymorphisms
    rodents, 274
    smokers, 273–274
  prospects for addiction studies, 218
  subtypes in mesolimbic system and nicotine reinforcement, 211–213, 270
NMDAR. *See N*-Methyl-D-aspartate receptor
Nociceptin, central amygdala alcohol dependence studies, 301–302
NPY. *See* Neuropeptide Y
Nuclear factor-κB (NF-κB), psychostimulant-induced structural plasticity, 87
Nucleus accumbens (NAcc)
  acute reinforcement, 45–46
  AMPA receptor transmission effects of cocaine
    chronic administration studies, 122–123
    overview, 121–122
    prospects for study, 129–130
    receptor trafficking and cocaine-induced plasticity, 123–124
    reinstatement of drug seeking
      GluA1 subunit-containing receptors, 124–127
      GluA2 subunit-containing receptors, 127–129
  CREB activation
    behavioral consequences, 101–103
    cellular and molecular consequences, 99–101
    drug reward circuitry, 103–104
  dynorphin
    behavioral consequences of induction, 102–103
    drug reward role, 103–104
  lesion studies, 47
  mesocorticolimbic dopamine pathway, 45
  opiate memory and glutamate receptors, 174–175
  optogenetics, 66–67
  relapse neurobiology, 49–50, 52
  reward circuitry, 72–75, 95–96
  structural plasticity, 75–81
  THC effects on synaptic transmission, 339



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



O
Obstruction Box, 16
OFC. *See* Orbitofrontal cortex
Opioid addiction
  glutamate receptors in memory mechanisms
    ascending dopamine pathways, 176–177
    basolateral amygdala outputs, 175–176
    conditioned reinforcement, 171
    conditioned reward and aversion, 170–171
    extinction and reinstatement, 171, 173
    hippocampus, 176
    overview, 172
    prefrontal-accumbens pathways, 174–175
    prospects for study, 177
    systems perspective, 173–174
  locus coeruleus
    anatomy, 161
    cellular plasticity changes, 161–163
    structural plasticity changes, 163
  medications
    development
      experimental strategies, 199–202
      historical perspective, 2–3
    opioid choice effects
      buprenorphine, 203–204
      implications for drug development, 205–206
      non-μ opioid medications, 206–207
      opioid agonists, 205
      opioid antagonists, 202–203
    prospects for study, 207–208
    types, 202–203
  memory mosaic, 169–170
  motivation, reward, and reinforcement, 183–184
  physical dependence, 153–154
  structural plasticity, 81
  ventral tegmental area
    acute changes
      neuronal activity, 154–155
      synaptic plasticity, 155–156
    anatomy, 154–155, 185–186
    chronic changes
      structural and cellular plasticity, 158–161
      synaptic plasticity, 156–158
    dopamine-dependent reinforcement, 184
    motivation and $GABA_A$ receptors
      brain-derived neurotrophic factor in switching, 191–192
      inhibitory and excitatory properties, 187–188
      integrated model of motivation, 192–193
      motivational switching mechanism, 190–191
      overview, 187
      signaling switch mechanisms, 188–189
    nondeprived/deprived hypothesis, 184
Opioid receptors
  alcoholism and μ-opioid receptor
    A118G polymorphism studies, 310–313
    naltrexone studies, 310, 313–315
    overview, 309–310
  κ-opioid receptor, CREB modulation, 101–103
Optogenetics
  brain slice studies, 65–66
  lasers, 65
  opsin modulation of neural circuits, 64–65
  overview, 63–64
  prospects, 67
  strategies in vivo, 66–67
Orbitofrontal cortex (OFC)
  mesocorticolimbic dopamine pathway, 45
  psychostimulants and dendritic morphology, 49
  relapse neurobiology, 50, 52

P
Pedunculopontine tegmental nucleus (PPTg), relapse neurobiology, 52
PFC. *See* Prefrontal cortex
Phencyclidine, structural plasticity effects, 81
PKA. *See* Protein kinase A
PKC. *See* Protein kinase C
Plasticity. *See* Structural plasticity; *specific brain areas*
POMC. *See* Proopiomelanocortin
Postsynaptic density (PSD), psychostimulant-induced neuroadaptation, 82–84
PPTg. *See* Pedunculopontine tegmental nucleus
Prefrontal cortex (PFC)
  cocaine addiction studies, 48
  drug-seeking behavior role, 48
  mesocorticolimbic dopamine pathway, 45
  nicotine effects in adolescents
    cognitive performance impact in later life, 228–231
    immediate effects, 225–226
    long-term consequences, 228–229
    mGluR2 expression, 227
    nicotinic acetylcholine receptor expression, 225–228
    prospects for study, 231
    vulnerability versus adult brain, 224–225
  opiate memory and glutamate receptors, 174–175
  optogenetics, 67
  psychostimulants and dendritic morphology, 49
  relapse neurobiology, 49–52
  reward circuitry, 72–75
  structural plasticity, 75–76
Proopiomelanocortin (POMC), nicotine effects on neurons, 217–218
Protein kinase A (PKA), AMPA receptor phosphorylation in nucleus accumbens, 125–126



© 2012 by Cold Spring Harbor Laboratory Press

This is a free sample of content from Addiction.
Click here for more information or to buy the book.



Protein kinase C (PKC), AMPA receptor phosphorylation in nucleus accumbens, 127–128
PSD. *See* Postsynaptic density
Punishment, resistance in animal addiction, 15–16

## Q

Quinine adulteration model, 15

## R

Relapse, neurobiology, 49–53
Rho, psychostimulant-induced structural plasticity, 88–89
rMTg. *See* Mesopontine rostromedial tegmental nucleus

## S

Shock, punishment resistance in animal addiction, 16
Smoking. *See* Nicotine
Stages, addiction, 44–45
Striatum. *See* Dorsal striatum
Structural plasticity. *See also* Dendritic morphology
  ecstasy effects, 81
  nicotine effects, 81
  nucleus accumbens, 75–79, 81
  opiate effects, 81
  phencyclidine effects, 81
  prefrontal cortex, 75–76
  prospects for study, 89
  psychostimulant mechanisms
    cyclic AMP response element-binding protein, 85, 87
    cyclin-dependent kinase-5, 87–88
    Fos, 85
    monocyte enhancing factor-2, 87–88
    nuclear factor-κB, 87
    overview, 84–86
    Rho, 88–89
  sex differences, 82
  techniques for study, 80
Suboxone, rationale for development, 3

## T

Tegmental pedunculopontine nucleus (TOPP), 184–185
THC. *See* Cannabinoids
TOPP. *See* Tegmental pedunculopontine nucleus

## V

Varenicline, nicotine addiction management, 5, 269
Ventral tegmental area (VTA)
  acute reinforcement, 46
  cocaine-evoked synaptic plasticity of excitatory transmission
    AMPA receptor
      AMPA receptor/NMDA receptor ratio, 112–116
      excitatory postsynaptic potentials, 114–115
    induction mechanism and mesolimbic dopamine, 112–114
    NMDA receptor excitatory postsynaptic potentials, 115–116
    synaptic function consequences, 115–116
  mesocorticolimbic dopamine pathway, 45, 238–239
  nicotinic acetylcholine receptors, 211–213
  opiate effects
    acute changes
      neuronal activity, 154–155
      synaptic plasticity, 155–156
    anatomy, 154–155, 185–186
    chronic change
      structural and cellular plasticity, 158–161
      synaptic plasticity, 156–158
    dopamine-dependent reinforcement, 184
    $GABA_A$ receptors in motivation
      brain-derived neurotrophic factor in switching, 191–192
      inhibitory and excitatory properties, 187–188
      integrated model of motivation, 192–193
      motivational switching mechanism, 190–191
      overview, 187
      signaling switch mechanisms, 188–189
  optogenetics, 65–67
  relapse neurobiology, 52
  reward circuitry, 72–75
VTA. *See* Ventral tegmental area
Vulnerability, addiction
  animal models
    diagnosis, 29, 31–33
    multi-symptomatic model of addiction, 29
    novelty responses, 34–37
    overview, 28–29
    rat responders, 29
    validation, 32, 34
  contributing factors
    behavioral consequences, 118
    complex interactions, 27–28
    drug type, 26
    overview, 25–26
    personality traits, 26
    prospects for study, 118
    reversal of drug-evoked plasticity, 116–118
  prospects for study, 37



© 2012 by Cold Spring Harbor Laboratory Press